Patient-specific three-dimensional concomitant dose from cone beam computed tomography exposure in image-guided radiotherapy

The effect of kV imaging dose on PTV and OAR planning constraints in lung SBRT using stereoscopic/monoscopic real-time tumor-monitoring system

PURPOSE

Quantify the impact of additional imaging doses on clinical dose constraints during lung stereotactic body radiotherapy (SBRT) treatment utilizing stereoscopic/monoscopic real-time tumor monitoring.

MATERIALS AND METHODS

Thirty lung SBRT patients treated with the volumetric arc therapy technique were randomly selected from the institutional clinical database. Contours of patients' and computed tomography data were extracted from the Eclipse treatment planning system, along with information regarding the treatment dose. Subsequently, patient-specific three-dimensional real-time imaging dose distributions were computed using a validated Monte Carlo simulation of the ExacTrac imaging. The 3D imaging dose was added to the treatment dose, and the influence of the imaging dose on clinical dose constraints was analyzed for planning target volume (PTV) and various organs at risk (OARs).

RESULTS

Among the 30 patients, 14 patients exhibited one or more failed OAR constraints based solely on the treatment dose, resulting in a total of 24 constraint failures. The addition of the real-time imaging dose altered the pass/fail criteria for one OAR constraint and two PTV constraints. The change in constraint due to additional imaging dose relative to the prescription dose was less than 1% for all patients, except for one case, where it reached 1.9%, which had remained below the threshold of 5% recommended by AAPM TG-180 guidelines. Furthermore, the additional imaging dose relative to the treatment dose resulted in an increase in OAR constraints ranging from 0 to 27% (mean of 0.8%), with nine cases exceeding 5%.

CONCLUSION

The current study represents the first attempt to investigate the impact of additional imaging doses on clinical planning constraints in real-time tumor monitoring during lung SBRT utilizing ExacTrac imaging system. The addition of an imaging dose will likely have minimal clinical impact.

A retrospective evaluation of inter-fraction motion in prostate cancer patients with involved nodes receiving prostate and pelvic ± para-aortic nodal irradiation

INTRODUCTION

The inter-fraction motion of pelvic ± para-aortic (PA) nodal volumes in prostate cancer patients with involved nodes is yet to be quantified and the optimal IGRT strategy for these patients is currently unknown.

METHODS

A single-centre retrospective evaluation was performed investigating inter-fraction motion in the prostate and involved nodal volumes of patients receiving pelvic ± PA nodal irradiation. Patients were selected for inclusion if they; were undergoing prostate + pelvic node +/- PA node radiation for prostate cancer with involved lymph nodes and had received daily online CBCT scans. The planning CT and subsequent CBCT images from each treatment fraction were selected for analysis.

RESULTS

Out of 567 CBCTs, from 20 patients, there were no incidences where independent lymph node displacement was >0.5 cm from planning volumes. Lymph node motion relative to prostate was >0.5 cm on 15 occasions out of 567 scans (2.6%). Where the difference between prostate and lymph nodes was >0.5 cm, this was always a result of the rectum causing variation in the prostate position, not a change in nodal position.

DISCUSSION

These results suggests that there is limited independent displacement between the involved pelvic ± PA nodal volumes and bony anatomy. Therefore, bony anatomy could be used as a lymph node match surrogate for prostate patients receiving nodal irradiation for active disease. The results also suggest additional emphasis should be placed on bowel preparation in these patients to reduce the risk of geographical miss.

CONCLUSION

In conclusion, the results of this evaluation suggests that there is limited independent displacement between the involved pelvic ± PA nodal volumes and bony anatomy. This provides evidence to trials investigating the role of pelvic ± PA nodal irradiation to ensure appropriate margins and IGRT strategies are used when investigating this further.

Organ dose prediction for patients undergoing radiotherapy CBCT chest examinations using artificial intelligence

PURPOSE

To propose an artificial intelligence (AI)-based method for personalized and real-time dosimetry for chest CBCT acquisitions.

METHODS

CT images from 113 patients who underwent radiotherapy treatment were collected for simulating thorax examinations using cone-beam computed tomography (CBCT) with the Monte Carlo technique. These simulations yielded organ dose data, used to train and validate specific AI algorithms. The efficacy of these AI algorithms was evaluated by comparing dose predictions with the actual doses derived from Monte Carlo simulations, which are the ground truth, utilizing Bland-Altman plots for this comparative analysis.

RESULTS

The absolute mean discrepancies between the predicted doses and the ground truth are (0.9 ± 1.3)% for bones, (1.2 ± 1.2)% for the esophagus, (0.5 ± 1.3)% for the breast, (2.5 ± 1.4)% for the heart, (2.4 ± 2.1)% for lungs, (0.8 ± 0.6)% for the skin, and (1.7 ± 0.7)% for integral. Meanwhile, the maximum discrepancies between the predicted doses and the ground truth are (14.4 ± 1.3)% for bones, (12.9 ± 1.2)% for the esophagus, (9.4 ± 1.3)% for the breast, (14.6 ± 1.4)% for the heart, (21.2 ± 2.1)% for lungs, (10.0 ± 0.6)% for the skin, and (10.5 ± 0.7)% for integral.

CONCLUSIONS

AI models that can make real-time predictions of the organ doses for patients undergoing CBCT thorax examinations as part of radiotherapy pre-treatment positioning were developed. The results of this study clearly show that the doses predicted by analyzed AI models are in close agreement with those calculated using Monte Carlo simulations.

Evaluation of a Scintillating Plastic Optical Fiber Device for Measuring kV-Cone Beam Computed Tomography Dose

BACKGROUND

Justification of imaging procedures such as cone beam computed tomography (CBCT) in radiotherapy makes no doubt. However, the CBCT composite dose is rarely reported or optimized, even though the repeated CBCT cumulative dose can be up to 3% of the prescription dose. This study aimed to evaluate the performance and utility of a new plastic scintillating optical fiber dosimeter for CBCT dosimetric quality assurance (QA) applications before a potential application in patient composite CBCT dosimetry.

METHODS

The dosimeter, made of 1 mm diameter plastic fiber, was installed under a linear accelerator treatment table and linked to photodetectors. The fiber impact on the fluence and dose delivered was respectively assessed with an electronic portal imaging device (EPID) and EBT3 Gafchromic® film. The presence of artifacts was visually evaluated on kV images. The dosimeter performances were determined for various acquisition parameters by comparison with ionization chamber values.

RESULTS

The maximum impact of the fiber on the fluence measured by the EPID was -1.2% for the 6 MV flattening filter-free beam. However, the fiber did not alter the film dose profile when measured for all the beams tested. The fiber was not visible at energies ≥ 80 kV and was merely visible on the CBCT images. When the rate of images per second or mA was changed, the maximum relative difference between the device and the ionization chamber CTDIs was <5%. Changing collimation led to a -7.2% maximum relative difference with an absolute dose difference that was insignificant (-0.3 mGy). Changing kV was associated with a -8.7% maximum relative difference, as published in the literature.

CONCLUSIONS

The dosimeter may be a promising device for CBCT recurrent dosimetry quality control or dose optimization. According to these results, further developments are in progress in order to adapt the solution to the measurement of patient composite CBCT doses.

Estimation of secondary cancer projected risk after partial breast irradiation at the 1.5 T MR-linac

PURPOSE

For patients treated with partial breast irradiation (PBI), potential long-term treatment-related toxicities are important. The 1.5 T magnetic resonance guided linear accelerator (MRL) offers excellent tumor bed visualization and a daily treatment plan adaption possibility, but MRL-specific electron stream and return effects may cause increased dose deposition at air-tissue interfaces. In this study, we aimed to investigate the projected risk of radiation-induced secondary malignancies (RISM) in patients treated with PBI at the 1.5 T MRL.

METHODS

Projected excess absolute risk values (EARs) for the contralateral breast, lungs, thyroid and esophagus were estimated for 11 patients treated with PBI at the MRL and compared to 11 patients treated with PBI and 11 patients treated with whole breast irradiation (WBI) at the conventional linac (CTL). All patients received 40.05 Gy in 15 fractions. For patients treated at the CTL, additional dose due to daily cone beam computed tomography (CBCT) was simulated. The t‑test with Bonferroni correction was used for comparison.

RESULTS

The highest projected risk for a radiation-induced secondary cancer was found for the ipsilateral lung, without significant differences between the groups. A lower contralateral breast EAR was found for MRL-PBI (EAR = 0.89) compared to CTL-PBI (EAR = 1.41, p = 0.01), whereas a lower thyroid EAR for CTL-PBI (EAR = 0.17) compared to MRL-PBI (EAR = 0.33, p = 0.03) and CTL-WBI (EAR = 0.46, p = 0.002) was observed. Nevertheless, when adding the CBCT dose no difference between thyroid EAR for CTL-PBI compared to MRL-PBI was detected.

CONCLUSION

Better breast tissue visualization and the possibility for daily plan adaption make PBI at the 1.5 T MRL particularly attractive. Our simulations suggest that this treatment can be performed without additional projected risk of RISM.

Dose estimation for cone-beam computed tomography in image-guided radiation therapy using mesh-type reference computational phantoms and assuming head and neck cancer

This study aimed to estimate the additional dose the cone-beam computed tomography (CBCT) system integrated into the Varian TrueBeam linear accelerator delivers to a patient with head and neck cancer using mesh-type International Commission on Radiological Protection reference computational phantoms. In the first part, for use as a benchmark for the accuracy of the Monte Carlo geometry of CBCT, Particle and Heavy Ion Transport code System (PHITS) calculations were confirmed against measured lateral and depth dose profiles using a computed tomography dose profiler. After obtaining good agreement, organ dose calculations were performed by PHITS using mesh-type reference computational phantom (MRCP) and irradiating the neck region; the effective dose was calculated utilising absorbed organ doses and tissue weighting factors for male and female MRCP. Substantially, it has been found that the effective doses for male and female MRCP are 0.81 and 1.06 mSv, respectively. As this study aimed to assess the imaging dose from the CBCT system used in image-guided radiation therapy, it is required to take into account this dose in terms of both the target organ and surrounding tissues. Although the absorbed organ dose values and effective dose values obtained for both MRCP males and females were small, attention should be paid to the additional dose resulting from CBCT. This study can create awareness on the importance of doses arising from imaging techniques, especially CBCT.

Construction of Prediction Model of Radiotherapy Set-Up Errors in Patients with Lung Cancer

Objective

This study intends to construct an error distribution prediction model and analyze its parameters and analyzes the boundary size of CTV extension to PTV, so as to provide a reference for lung cancer patients to control clinical set-up errors and radiotherapy planning.

Methods

The prior SBRT set-up error data of 50 patients with lung cancer treated by medical linear accelerator were selected, the Gaussian mixture model was adopted to construct the error distribution prediction model, and the model parameters were solved, based on which the emission boundary from CTV to PTV was calculated.

Results

According to the analysis of the model parameters, the spatial distribution of set-up errors is mainly concentrated in the direction of four central points (μ 1 ~ μ 4), and the error is smaller in the Vrt direction (-0.991~2.808 mm) and Lat direction (-0.447~1.337 mm) and larger in the Lng direction (-1.065~4,463 mm). The possibility of offset of set-up errors in μ 2 and μ 3 direction (0.4440, 02198) is greater than that of μ 1 and μ 4 (0.1767, 0.1595). The standard deviation of set-up errors can reach 0.538 mm. The theoretical expansion boundary of CTV to PTV in Vrt, Lng, and Lat can be calculated as 1.7963 mm, 2.3749 mm, and 0.6066 mm.

Conclusion

The GMM Gaussian mixture model can quantitatively describe and predict the set-up errors distribution of lung cancer patients and can obtain the emission boundary of CTV to PTV, which provides a reference for radiotherapy set-up errors control and tumor planning target expansion of lung cancer patients without SBRT.

CBCT imaging: a simple approach for optimising and evaluating concomitant imaging doses, based on patient-specific attenuation, during radiotherapy pelvis treatment

Objectives:

A simple, robust method, for optimising cone-beam CT (CBCT) dose and image quality for pelvis treatment, based on patient-specific attenuation.

Methods:

Methods were investigated for grouping patients into four imaging categories (small [S], medium [M], large [L], extra large [XL]), based on planning-CT CTDIvol, and phantoms constructed to represent each group. CBCTs with varying kV, mA and ms honed in on the best settings, with a bladder noise of 25 HU. A patient pilot study clinically verified the new imaging settings.

Results:

The planning CTDIvol is a reliable method for grouping patients. Phantom measurements from the S, M and L groups show doses significantly reduced (19–83% reduction), whilst the XL group required an increase of 39%. Phantom TLD measurements showed the number of scans needed to increase rectal organ at risk (OAR) dose by 1 Gy was 143 (S group) and 50 (M group). Images were qualitatively assessed as sufficient by clinicians.

Conclusion:

Patient-specific CBCT modes are in use clinically with dose reductions across all modes except Pelvis XL, keeping doses ALARP and images optimal. Consideration of OAR doses controls the number of CBCTs allowed to ensure adherence to OAR tolerance. Reporting CBCT doses in “scans per Gray” allows clinicians to make informed decisions regarding the imaging schedule and concomitant doses.

Advances in knowledge:

Patient grouping at planning CT, using CTDIvol, allows for CBCT imaging protocols to be selected based on patient specific attenuation. Reporting OAR doses in terms of “scans per Gray” allows translation of imaging dose risk to the Oncologist.

Generation of material-specific energy deposition kernels for kilovoltage x-ray dose calculations

PURPOSE

Dose calculation of kilovoltage x rays used in Image-Guided Radiotherapy has been investigated in recent years using various methods. Among these methods are model-based ones that suffer from inaccuracies in high-density materials and at interfaces when used in the kilovoltage energy range. The main reason for this is the use of water energy deposition kernels and simplifications employed such as density scaling in heterogeneous media. The purpose of this study was to produce and characterize material-specific energy deposition kernels, which could be used for dose calculations in this energy range. These kernels will also have utility in dose calculations in superficial radiation therapy and orthovoltage beams utilized in small animal irradiators.

METHODS

Water energy deposition kernels with various resolutions; and high-resolution, material-specific energy deposition kernels were generated in the energy range of 10-150 kVp, using the EGSnrc Monte Carlo toolkit. The generated energy deposition kernels were further characterized by calculating the effective depth of penetration, the effective radial distance, and the effective lateral distance. A simple benchmarking of the kernels against Monte Caro calculations has also been performed.

RESULTS

There was good agreement with previously reported water kernels, as well as between kernels with different resolution. The evaluation of effective depth of penetration, and radial and laterals distances, defines the relationship between energy, material density, and the shape of the material-specific kernels. The shape of these kernels becomes more forwardly scattered as the energy and material density are increased. The comparison of the dose calculated using the kernels with Monte Carlo provides acceptable results.

CONCLUSIONS

Water and material-specific energy deposition kernels in the kilovoltage energy range have been generated, characterized, and compared to previous work. These kernels will have utility in dose calculations in this energy range once algorithms capable of employing them are fully developed.

Evaluation of the relationship between phantom position and computed tomography dose index in cone beam computed tomography when assuming breast irradiation

This study aims to investigate the influence of the phantom position on weighted computed tomography dose index (CTDIw ) in cone beam computed tomography (CBCT) when assuming breast irradiation. Computed tomography dose index (CTDI) was measured by the x-ray volume imaging of CBCT using parameters for image-guided radiation therapy (IGRT) in right breast irradiation. The measurement points of CTDI ranged from 0 (center) to 16 cm in the right-left (RL) direction, and from 0 (center) to 7.5 cm in the anterior-posterior (AP) direction, which assumed right breast irradiation. A nonuniform change exists in the relative value of CTDIw when the phantom deviated from the isocenter of CBCT. The CTDIw was ~30% lower compared with the value at the isocenter of CBCT when the phantom deviated 7.5 and 16 cm at the AP and RL directions, respectively. This study confirmed the influence of the phantom position on the CTDI values of CBCT. The CTDI measured at the isocenter of CBCT overestimates that measured at the irradiation center of the breast.

Contribution of Imaging to Organs at Risk Dose during Lung Stereotactic Body Radiation Therapy

Background:

The use of imaging is indispensable in modern radiation therapy, both for simulation and treatment delivery. For safe and sure utilization, dose delivery from imaging must be evaluated.

Objective:

This study aims to investigate the dose to organ at risk (OAR) delivered by imaging during lung stereotactic body radiation therapy (SBRT) and to evaluate its contribution to the treatment total dose.

Material and Methods:

In this retrospectively study, imaging total dose to organs at risk (OARs) (spinal cord, esophagus, lungs, and heart) and effective dose were retrospectively evaluated from 100 consecutive patients of a single institution who had lung SBRT. For each patient, dose was estimated using Monte-Carlo convolution for helical computed tomography (helical CT), Four-Dimensional CT (4D-CT), and kilovoltage Cone-Beam CT (kV-CBCT). Helical CT and kV-CBCT dose were evaluated for the entire thorax acquisition, while 4D-CT dose was analyzed on upper lobe (UL) or lower lobe (LL) acquisition. Treatment dose was extracted from treatment planning system and compared to imaging total dose.

Results:

Imaging total dose maximum values were 117 mGy to the spinal cord, 127 mGy to the esophagus, 176 mGy to the lungs and 193 mGy to the heart. The maximum effective dose was 19.65 mSv for helical CT, 10.62 mSv for kV-CBCT, 25.95 mSv and 38.45 mSv for 4D-CT in UL and LL regions, respectively. Depending on OAR, treatment total dose was higher from 1.7 to 8.2 times than imaging total dose. Imaging total dose contributed only to 0.3% of treatment total dose.

Conclusion:

Imaging dose delivered with 4D-CT to the OARs is higher than those of others modalities. The heart received the highest imaging dose for both UL and LL. Total imaging dose is negligible since it contributed only to 0.3% of treatment total dose.

Head and neck radiotherapy on the MR linac: a multicenter planning challenge amongst MRIdian platform users

Purpose

Purpose of this study is to evaluate plan quality on the MRIdian (Viewray Inc., Oakwood Village, OH, USA) system for head and neck cancer (HNC) through comparison of planning approaches of several centers.

Methods

A total of 14 planners using the MRIdian planning system participated in this treatment challenge, centrally organized by ViewRay, for one contoured case of oropharyngeal carcinoma with standard constraints for organs at risk (OAR). Homogeneity, conformity, sparing of OARs, and other parameters were evaluated according to The International Commission on Radiation Units and Measurements (ICRU) recommendations anonymously, and then compared between centers. Differences amongst centers were assessed by means of Wilcoxon test. Each plan had to fulfil hard constraints based on dose–volume histogram (DVH) parameters and delivery time. A plan quality metric (PQM) was evaluated. The PQM was defined as the sum of 16 submetrics characterizing different DVH goals.

Results

For most dose parameters the median score of all centers was higher than the threshold that results in an ideal score. Six participants achieved the maximum number of points for the OAR dose parameters, and none had an unacceptable performance on any of the metrics. Each planner was able to achieve all the requirements except for one which exceeded delivery time. The number of segments correlated to improved PQM and inversely correlated to brainstem D_0.1cc and to Planning Target Volume1 (PTV) D_0.1cc. Total planning experience inversely correlated to spinal canal dose.

Conclusion

Magnetic Resonance Image (MRI) linac-based planning for HNC is already feasible with good quality. Generally, an increased number of segments and increasing planning experience are able to provide better results regarding planning quality without significantly prolonging overall treatment time.

Supplementary Information

The online version of this article (10.1007/s00066-021-01771-8) contains supplementary material, which is available to authorized users.

[Management of image guidance doses delivered during radiotherapy]

Image-guided radiotherapy (IGRT) has become a standard irradiation technique to improve the clinical outcome of patients in terms of toxicity and local control due to better targeting of radiation during the irradiation fraction. Positioning imaging systems, whether embedded or not, such as kV for 2×2D acquisitions and especially kVCBCT for 3D acquisitions are however irradiating in a large volume including the target volume but also healthy tissue, with a theoretical risk of increased toxicity and second cancer. It therefore appears very important both to optimize the absorbed dose due to IGRT practice but also to report it, especially in case of kVCBCT. The AAPM report published in 2018 (« Image guidance doses delivered during radiotherapy: Quantification, management, and reduction ») proposes a management of image guidance doses delivered during radiotherapy. This report is the basis of this focus article that aims at giving orders of magnitude and proposing a management of image guidance doses delivered during radiotherapy in clinical practice. The dose delivered per kVCBCT is about 0.5 to 2 cGy at isocenter according to treatment site. As long as the calculation algorithms are not available in the treatment planning systems, it seems appropriate to use at least the published dose orders of magnitude. This estimate should ultimately allow the clinician to decide on the therapeutic strategy in the event of accumulation of positioning imaging sessions.

Comprehensive characterization of ExacTrac stereoscopic image guidance system using Monte Carlo and Spektr simulations

The purpose of this work is to develop accurate computational methods to comprehensively characterize and model the clinical ExacTrac imaging system, which is used as an image guidance system for stereotactic treatment applications. The Spektr toolkit was utilized to simulate the spectral and imaging characterization of the system. Since Spektr only simulates the primary beam (ignoring scatter), a full model of ExacTrac was also developed in Monte Carlo (MC) to characterize the imaging system. To ensure proper performance of both simulation models, Spektr and MC data were compared to the measured spectral and half value layers (HVLs) values. To validate the simulation results, x-ray spectra of the ExacTrac system were measured for various tube potentials using a CdTe spectrometer with multiple added narrow collimators. The raw spectra were calibrated using a ⁵⁷Co source and corrected for the escape peaks and detector efficiency. HVLs in mm of Al for various energies were measured using a calibrated RaySafe detector. Spektr and MC HVLs were calculated and compared to the measured values. The patient surface dose was calculated for different clinical imaging protocols from the measured air kerma and HVL values following the TG-61 methodology. The x-ray focal spot was measured by slanted edge technique using gafchromic films. ExacTrac imaging system beam profiles were simulated for various energies by MC simulation and the results were benchmarked by experimentally acquired beam profiles using gafchromic films. The effect of 6D IGRT treatment couch on beam hardening, dynamic range of the flat panel detector and scatter effect were determined using both Spektr simulation and experimental measurements. The measured and simulated spectra (of both MC and Spektr) for various kVps were compared and agreed within acceptable error. As another validation, the measured HVLs agreed with the Spektr and MC simulated HVLs on average within 1.0% for all kVps. The maximum and minimum patient surface doses were found to be 1.06 mGy for shoulder (high) and 0.051 mGy for cranial (low) imaging protocols, respectively. The MC simulated beam profiles were well matched with experimental results and replicated the penumbral slopes, the heel effect, and out-of-field regions. Dynamic range of detector (in terms of air kerma at detector surface) was found to be in the range of [6.1 × 10^-6, 5.3 × 10^-3] mGy. Accurate MC and Spektr models of the ExacTrac image guidance system were successfully developed and benchmarked via experimental validation. While patient surface dose for available imaging protocols were reported in this study, the established MC model may be used to obtain 3D imaging dose distribution for real patient geometries.

Characterisation of Time-of-Flight (ToF) imaging system for application in monitoring deep inspiration breath-hold radiotherapy (DIBH-RT)

The purpose of this study is to develop a method for characterisation of time-of-flight (ToF) imaging system for application in deep inspiration breath-hold radiotherapy (DIBH-RT). The performance of an Argos 3D P330 ToF camera (Bluetechnix, Austria) was studied for patient surface monitoring during DIBH-RT using a phantom to simulate the intra-patient and inter-patient stability of the camera. Patient setup error was also simulated by positioning the phantom at predefined shift positions (2, 5 and 10 mm) from the isocentre. The localisation accuracy of the phantom was measured using ToF imaging system and repeated using CBCT imaging alone (CBCT) and simultaneously using ToF imaging during CBCT imaging (ToF-CBCT). The mean and SD of the setup errors obtained from each of the imaging methods were calculated. Student t-test was used to compare the mean setup errors. Correlation and Bland-Altman analysis were also performed. The intra-and inter-patient stability of the camera were within 0.31 mm and 0.74 mm, respectively. The localisation accuracy in terms of the mean ±SD of the measured setup errors were 0.34 ± 0.98 mm, 0.12 ± 0.34 mm, and −0.24 ± 1.42 mm for ToF, CBCT and ToF-CBCT imaging, respectively. A strong correlation was seen between the phantom position and the measured position using ToF (r = 0.96), CBCT (r = 0.99) as well as ToF-CBCT (r = 0.92) imaging. The limits of agreement from Bland Altman analysis between the phantom position and ToF, CBCT and ToF-CBCT measured positions were −1.52, 2.31 mm, −0.55, 0.78 mm; and −3.03, 2.55 mm, respectively. The sensor shows good stability and high accuracy comparable to similar sensors in the market. The method developed is useful for characterisation of an optical surface imaging system for application in monitoring DIBH-RT.

A review of Image Guided Radiation Therapy in head and neck cancer from 2009-201 - Best Practice Recommendations for RTTs in the Clinic

Radiation therapy (RT) is beneficial in Head and Neck Cancer (HNC) in both the definitive and adjuvant setting. Highly complex and conformal planning techniques are becoming standard practice in delivering increased doses in HNC. A sharp falloff in dose outside the high dose area is characteristic of highly complex techniques and geometric uncertainties must be minimised to prevent under dosage of the target volume and possible over dosage of surrounding critical structures. CTV-PTV margins are employed to account for geometric uncertainties such as set up errors and both interfraction and intrafraction motion. Robust immobilisation and Image Guided Radiation Therapy (IGRT) is also essential in this group of patients to minimise discrepancies in patient position during the treatment course. IGRT has evolved with increased 2-Dimensional (2D) and 3-Dimensional (3D) IGRT modalities available for geometric verification. 2D and 3D IGRT modalities are both beneficial in geometric verification while 3D imaging is a valuable tool in assessing volumetric changes that may have dosimetric consequences for this group of patients. IGRT if executed effectively and efficiently provides clinicians with confidence to reduce CTV-PTV margins thus limiting treatment related toxicities in patients. Accumulated exposure dose from IGRT vary considerably and may be incorporated into the treatment plan to avoid excess dose. However, there are considerable variations in the application of IGRT in RT practice. This paper aims to summarise the advances in IGRT in HNC treatment and provide clinics with recommendations for an IGRT strategy for HNC in the clinic.

Validation of histogram-based virtual source models for different IGRT kV-imaging systems

PURPOSE

Image-guided radiotherapy (IGRT) improves tumor control but its intensive use may entrain late side effects caused by the additional imaging doses. There is a need to better quantify the additional imaging doses, so they can be integrated in the therapeutic workflow. Currently, no dedicated software enables to compute patient-specific imaging doses on a wide range of systems and protocols. As a first step toward this objective, we propose a common methodology to model four different kV-imaging systems used in radiotherapy (Varian's OBI, Elekta's XVI, Brainlab's ExacTrac, and Accuray's Cyberknife) using a new type of virtual source model based on Monte Carlo calculations.

METHODS

We first describe our method to build a simplified description of the photon output, or virtual source models (VSMs), of each imaging system. Instead of being constructed using measurement data, as it is most commonly the case, our VSM is used as the summary of the phase-space files (PSFs) resulting from a first Monte Carlo simulation of the considered x-ray tube. Second, the VSM is used as a photon generator for a second MC simulation in which we compute the dose. Then, the proposed VSM is thoroughly validated against standard MC simulation using PSFs on the XVI system. Last, each modeled system is compared to profiles and depth-dose-curve measurements performed in homogeneous phantom.

RESULTS

Comparisons between PSF-based and VSM-based calculations highlight that VSMs could provide equivalent dose results (within 1% of difference) than PSFs inside the imaging field-of-view (FOV). In contrast, VSMs tend to underestimate (for up to 20%) calculated doses outside of the imaging FOV due to the assumptions underlying the VSM construction. In addition, we showed that the use of VSMs allows reducing calculation time by at least a factor of 2.8. Indeed, for identical simulation times, statistical uncertainties on dose distributions computed using VSMs were much lower than those obtained from PSF-based calculations.

CONCLUSIONS

For each of the four imaging systems, VSMs were successfully validated against measurements in homogeneous phantoms, and are therefore ready to be used for future preclinical studies in heterogeneous or anthropomorphic phantoms. The cross system modeling methodology developed here should enable, later on, to estimate precisely and accurately patient-specific 3D dose maps delivered during a large range of kV-imaging procedures.

Image guidance and positioning accuracy in clinical practice: influence of positioning errors and imaging dose on the real dose distribution for head and neck cancer treatment

BACKGROUND

Modern radiotherapy offers the possibility of highly accurate tumor treatment. To benefit from this precision at its best, regular positioning verification is necessary. By the use of image-guided radiotherapy and the application of safety margins the influence of positioning inaccuracies can be counteracted. In this study the effect of additional imaging dose by set-up verification is compared with the effect of dose smearing by positioning inaccuracies for a collective of head-and-neck cancer patients.

METHODS

This study is based on treatment plans of 40 head-and-neck cancer patients. To evaluate the imaging dose several image guidance scenarios with different energies, techniques and frequencies were simulated and added to the original plan. The influence of the positioning inaccuracies was assessed by the use of real applied table shifts for positioning. The isocenters were shifted back appropriately to these values to simulate that no positioning correction had been performed. For the single fractions the shifted plans were summed considering three different scenarios: The summation of only shifted plans, the consideration of the original plan for the fractions with set-up verification, and the addition of the extra imaging dose to the latter. For both effects (additional imaging dose and dose smearing), plans were analyzed and compared considering target coverage, sparing of organs at risk (OAR) and normal tissue complication probability (NTCP).

RESULTS

Daily verification of the patient positioning using 3D imaging with MV energies result in non-negligible high doses. kV imaging has only marginal influence on plan quality, primarily related to sparing of organs at risk, even with daily 3D imaging. For this collective, sparing of organs at risk and NTCP are worse due to potential positioning errors.

CONCLUSION

Regular set-up verification is essential for precise radiation treatment. Relating to the additional dose, the use of kV modalities is uncritical for any frequency and technique. Dose smearing due to positioning errors for this collective mainly resulted in a decrease of OAR sparing. Target coverage also suffered from the positioning inaccuracies, especially for individual patients. Taking into account both examined effects the relevance of an extensive IGRT is clearly present, even at the expense of additional imaging dose and time expenditure.

Imaging Dose, Cancer Risk and Cost Analysis in Image-guided Radiotherapy of Cancers

The purpose of this retrospective study is to evaluate the cumulative imaging doses, the associated cancer risk and the cost related to the various radiological imaging procedures in image-guided radiotherapy of cancers. Correlations between patients’ size and Monte Carlo simulated organ doses were established and validated for various imaging procedures, and then used for patient-specific organ dose estimation of 4,832 cancer patients. The associated cancer risk was estimated with published models and the cost was calculated based on the standard billing codes. The average (range) cumulative imaging doses to the brain, lungs and red bone marrow were 38.0 (0.5–177.3), 18.8 (0.4–246.5), and 49.1 (0.4–274.4) cGy, respectively. The associated average (range) lifetime attributable risk of cancer incidence per 100,000 persons was 78 (0–2798), 271 (1–8948), and 510 (0–4487) for brain cancer, lung cancer and leukemia, respectively. The median (range) imaging cost was $5256 (4268–15896) for the head scans, $5180 (4268–16274) for the thorax scans, and $7080 (4268–15288) for the pelvic scans, respectively. The image-guidance procedures and the accumulated imaging doses should be incorporated into clinical decision-making to personalize radiotherapy for individual patients.

Image guidance doses delivered during radiotherapy: Quantification, management, and reduction: Report of the AAPM Therapy Physics Committee Task Group 180

BACKGROUND

With radiotherapy having entered the era of image guidance, or image-guided radiation therapy (IGRT), imaging procedures are routinely performed for patient positioning and target localization. The imaging dose delivered may result in excessive dose to sensitive organs and potentially increase the chance of secondary cancers and, therefore, needs to be managed.

AIMS

This task group was charged with: a) providing an overview on imaging dose, including megavoltage electronic portal imaging (MV EPI), kilovoltage digital radiography (kV DR), Tomotherapy MV-CT, megavoltage cone-beam CT (MV-CBCT) and kilovoltage cone-beam CT (kV-CBCT), and b) providing general guidelines for commissioning dose calculation methods and managing imaging dose to patients.

MATERIALS & METHODS

We briefly review the dose to radiotherapy (RT) patients resulting from different image guidance procedures and list typical organ doses resulting from MV and kV image acquisition procedures.

RESULTS

We provide recommendations for managing the imaging dose, including different methods for its calculation, and techniques for reducing it. The recommended threshold beyond which imaging dose should be considered in the treatment planning process is 5% of the therapeutic target dose.

DISCUSSION

Although the imaging dose resulting from current kV acquisition procedures is generally below this threshold, the ALARA principle should always be applied in practice. Medical physicists should make radiation oncologists aware of the imaging doses delivered to patients under their care.

CONCLUSION

Balancing ALARA with the requirement for effective target localization requires that imaging dose be managed based on the consideration of weighing risks and benefits to the patient.

Estimation of patient-specific imaging dose for real-time tumour monitoring in lung patients during respiratory-gated radiotherapy

PURPOSE

To quantify the patient-specific imaging dose for real-time tumour monitoring in the lung during respiratory-gated stereotactic body radiotherapy (SBRT) in clinical cases using SyncTraX.

METHODS AND MATERIALS

Ten patients who underwent respiratory-gated SBRT with SyncTraX were enrolled in this study. The imaging procedure for real-time tumour monitoring using SyncTraX was simulated using Monte Carlo. We evaluated the dosimetric effect of a real-time tumour monitoring in a critical organ at risk (OAR) and the planning target volume (PTV) over the course of treatment. The relationship between skin dose and gating efficiency was also investigated.

RESULTS

For all patients, the mean D50 to the PTV, ipsilateral lung, liver, heart, spinal cord and skin was 118.3 (21.5-175.9), 31.9 (9.5-75.4), 15.4 (1.1-31.6), 10.1 (1.3-18.1), 25.0 (1.6-101.8), and 3.6 (0.9-7.1) mGy, respectively. The mean D2 was 352.0 (26.5-935.8), 146.4 (27.3-226.7), 90.7 (3.6-255.0), 42.2 (4.8-82.7), 88.0 (15.4-248.5), and 273.5 (98.3-611.6) mGy, respectively. The D2 of the skin dose was found to increase as the gating efficiency decreased.

CONCLUSIONS

The additional dose to the PTV was at most 1.9% of the prescribed dose over the course of treatment for real-time tumour monitoring. For OARs, we could confirm the high dose region, which may not be susceptible to radiation toxicity. However, to reduce the skin dose from SyncTraX, it is necessary to increase the gating efficiency.

Quantification of the kV X-ray imaging dose during real-time tumor tracking and from three- and four-dimensional cone-beam computed tomography in lung cancer patients using a Monte Carlo simulation

Knowledge of the imaging doses delivered to patients and accurate dosimetry of the radiation to organs from various imaging procedures is becoming increasingly important for clinicians. The purposes of this study were to calculate imaging doses delivered to the organs of lung cancer patients during real-time tumor tracking (RTTT) with three-dimensional (3D), and four-dimensional (4D) cone-beam computed tomography (CBCT), using Monte Carlo techniques to simulate kV X-ray dose distributions delivered using the Vero4DRT. Imaging doses from RTTT, 3D-CBCT and 4D-CBCT were calculated with the planning CT images for nine lung cancer patients who underwent stereotactic body radiotherapy (SBRT) with RTTT. With RTTT, imaging doses from correlation modeling and from monitoring of imaging during beam delivery were calculated. With CBCT, doses from 3D-CBCT and 4D-CBCT were also simulated. The doses covering 2-cc volumes (D2cc) in correlation modeling were up to 9.3 cGy for soft tissues and 48.4 cGy for bone. The values from correlation modeling and monitoring were up to 11.0 cGy for soft tissues and 59.8 cGy for bone. Imaging doses in correlation modeling were larger with RTTT. On a single 4D-CBCT, the skin and bone D2cc values were in the ranges of 7.4-10.5 cGy and 33.5-58.1 cGy, respectively. The D2cc from 4D-CBCT was approximately double that from 3D-CBCT. Clinicians should Figure that the imaging dose increases the cumulative doses to organs.

Investigation of the radiation dose from cone-beam CT for image-guided radiotherapy: A comparison of methodologies

Four methodologies were evaluated for quantifying kilovoltage cone‐beam computed tomography (CBCT) dose: the Cone‐Beam Dose Index (CBDI), IAEA Report 5 recommended methodology (IAEA), the AAPM Task Group 111 methodology (TG111), and the current dose metric; the Computed Tomography Dose Index (CTDI) on two commercial Varian cone‐beam CT imaging systems; the Clinac iX On‐Board Imager (OBI); and the TrueBeam X‐ray Imaging system (XI). The TG111 methodology measured the highest overall dose (21.199 ± 0.035 mGy OBI and 22.420 ± 0.002 XI for pelvis imaging) due to the full scatter of the TG111 phantom and was within 5% of CTDI measurements taken using a full scatter TG111 phantom and 30‐cm film strips. CBDI measured the second highest overall dose, within 10% of the TG111, with IAEA measuring the third highest dose. For head CBCT protocols, CBDI measured the highest dose, followed by IAEA. The CTDI method measured lowest across all scan modes highlighting its limitations for CBCT dosimetry. The XI imaging system delivered lower doses for head and thorax scan modes and similar doses to the OBI system for pelvis scan modes due to additional beam hardening filtration in the XI system. The TG111 method measured the highest dose in the center of a CBCT scan during image guidance procedures; however, CBDI provided a good approximation to TG111 with existing CTDI equipment and may be more applicable clinically.

Phantom-based evaluation of dose exposure of ultrafast combined kV-MV-CBCT towards clinical implementation for IGRT of lung cancer

PURPOSE

Combined ultrafast 90°+90° kV-MV-CBCT within single breath-hold of 15s has high clinical potential for accelerating imaging for lung cancer patients treated with deep inspiration breath-hold (DIBH). For clinical feasibility of kV-MV-CBCT, dose exposure has to be small compared to prescribed dose. In this study, kV-MV dose output is evaluated and compared to clinically-established kV-CBCT.

METHODS

Accurate dose calibration was performed for kV and MV energy; beam quality was determined. For direct comparison of MV and kV dose output, relative biological effectiveness (RBE) was considered. CT dose index (CTDI) was determined and measurements in various representative locations of an inhomogeneous thorax phantom were performed to simulate the patient situation.

RESULTS

A measured dose of 20.5mGE (Gray-equivalent) in the target region was comparable to kV-CBCT (31.2mGy for widely-used, and 9.1mGy for latest available preset), whereas kV-MV spared healthy tissue and reduced dose to 6.6mGE (30%) due to asymmetric dose distribution. The measured weighted CTDI of 12mGE for kV-MV lay in between both clinical presets.

CONCLUSIONS

Dosimetric properties were in agreement with established imaging techniques, whereas exposure to healthy tissue was reduced. By reducing the imaging time to a single breath-hold of 15s, ultrafast combined kV-MV CBCT shortens patient time at the treatment couch and thus improves patient comfort. It is therefore usable for imaging of hypofractionated lung DIBH patients.

Abdominal imaging dose in radiology and radiotherapy - Phantom point dose measurements, effective dose and secondary cancer risk

PURPOSE

To compare abdominal imaging dose from 3D imaging in radiology (standard/low-dose/dual-energy CT) and radiotherapy (planning CT, kV cone-beam CT (CBCT)).

METHODS

Dose was measured by thermoluminescent dosimeters (TLD's) placed at 86 positions in an anthropomorphic phantom. Point, organ and effective dose were assessed, and secondary cancer risk from imaging was estimated.

RESULTS

Overall dose and mean organ dose comparisons yield significantly lower dose for the optimized radiology protocols (dual-source and care kV), with an average dose of 0.34±0.01 mGy and 0.54±0.01 mGy (average ± standard deviation), respectively. Standard abdominal CT and planning CT involve considerably higher dose (13.58 ± 0.18 mGy and 18.78±0.27 mGy, respectively). The CBCT dose show a dose fall-off near the field edges. On average, dose is reduced as compared with the planning or standard CT (3.79 ± 0.21 mGy for 220° rotation and 7.76 ± 0.37 mGy for 360°), unless the high-quality setting is chosen (20.30 ± 0.96 mGy). The mean organ doses show a similar behavior, which translates to the estimated secondary cancer risk. The modelled risk is in the range between 0.4 cases per million patient years (PY) for the radiological scans dual-energy and care kV, and 300 cases per million PY for the high-quality CBCT setting.

CONCLUSIONS

Modern radiotherapy imaging techniques (while much lower in dose than radiotherapy), involve considerably more dose to the patient than modern radiology techniques. Given the frequency of radiotherapy imaging, a further reduction in radiotherapy imaging dose appears to be both desirable and technically feasible.

Comprehensive Monte Carlo study of patient doses from cone-beam CT imaging in radiotherapy

Accurate knowledge of ionizing radiation dose from cone-beam CT (CBCT) imaging in radiotherapy is important to allow concomitant risks to be estimated and for justification of imaging exposures. This study uses a Monte Carlo CBCT model to calculate imaging dose for a wide range of imaging protocols for male and female patients. The Elekta XVI CBCT system was modeled using GATE and simulated doses were validated against measurements in a water tank and thorax phantom. Imaging dose was simulated in the male and female ICRP voxel phantoms for a variety of anatomical sites and imager settings (different collimators, filters, full and partial rotation). The resulting dose distributions were used to calculate effective doses for each scan protocol. The Monte Carlo simulated doses agree with validation measurements within 5% and 10% for water tank and thorax phantom respectively. Effective dose for head CBCT scans was generally lower for scans centred on the pituitary than the larynx (0.03 mSv versus 0.06 mSv for male ICRP phantom). Pelvis CBCT scan effective dose was higher for the female than male phantom (5.11 mSv versus 2.80 mSv for M15 collimator scan), principally due to the higher dose received by gonads for the female scan. Medium field of view thorax scan effective doses ranged from 1.38-3.19 mSv depending on scan length and phantom sex. Effective dose for half rotation thorax scans with offset isocentre varied by almost a factor of three depending on laterality of the isocentre, patient sex and imaged field length. The CBCT imaging doses simulated here reveal large variations in dose depending on imaging isocentre location, patient sex and partial rotation angles. This information may be used to estimate risks from CBCT and to optimize CBCT imaging protocols.

Risks and benefits of reducing target volume margins in breast tangent radiotherapy

This study investigates the potential benefits of planning target volume (PTV) margin reduction for whole breast radiotherapy in relation to dose received by organs at risk (OARs), as well as reductions in radiation-induced secondary cancer risk. Such benefits were compared to the increased radiation-induced secondary cancer risk attributed from increased ionizing radiation imaging doses. Ten retrospective patients' computed tomography datasets were considered. Three computerized treatment plans with varied PTV margins (0, 5 and 10 mm) were created for each patient complying with the Radiation Therapy Oncology Group (RTOG) 1005 protocol requirements. The BEIR VII lifetime attributable risk (LAR) model was used to estimate secondary cancer risk to OARs. The LAR was assessed for all treatment plans considering (a) doses from PTV margin variation and (b) doses from two (daily and weekly) kilovoltage cone beam computed tomography (kV CBCT) imaging protocols during the course of treatment. We found PTV margins from largest to smallest resulted in a mean OAR relative dose reduction of 31% (heart), 28% (lung) and 23% (contralateral breast) and the risk of radiation-induced secondary cancer by a relative 23% (contralateral breast) and 22% (contralateral lung). Daily image-guidance using kV CBCT increased the risk of radiation induced secondary cancer to the contralateral breast and contralateral lung by a relative 1.6-1.9% and 1.9-2.5% respectively. Despite the additional dose from kV CBCT for the two considered imaging protocols, smaller PTV margins would still result in an overall reduction in secondary cancer risk.

Volumetric image-guided highly conformal radiotherapy of the prostate bed: Toxicity analysis

AIM

To evaluate toxicity of high conformal image-guided radiotherapy of the prostate bed.

BACKGROUND

Radiotherapy of the prostate bed has a pivotal role in the post-operative and salvage settings, but few clinical data are available on the use of daily image guidance in combination with highly conformal techniques, and data on long-term results are lacking.

MATERIALS AND METHODS

We analyzed 118 patients irradiated on the prostate bed using conformal plans processed with a micro-multileaf collimator, and daily checking treatment set-up with a cone-beam CT system. Correlation between toxicity and clinical-dosimetric parameters was assessed by the Cox regression model and log-rank test. Survival analyses were performed with the Kaplan-Meier method.

RESULTS

Median follow-up was 54.08 months. Late grade ≥2 gastro-intestinal (GI) and genito-urinary (GU) toxicity were 3.4% and 4.2%, respectively. Actuarial 4-year late grade ≥2 GI and GU toxicities were 4% and 6%, respectively. Four-year relapse-free survival was 87%. At log-rank test, acute grade ≥2 GI toxicity is associated with the use of antihypertensives (p = 0.03), and there is a trend toward significance between the use of anticoagulants and late grade ≥2 GI toxicity (p = 0.07). At Cox analysis, acute grade ≥2 GU toxicity is correlated with the percentage of bladder volume receiving more than 65 Gy (p = 0.02, HR 1.87 CI 1.25-2.8), and the maximal dose to the rectum is correlated to the development of late grade ≥2 GI toxicity (p = 0.03, HR 2.75 CI 1.10-6.9).

CONCLUSIONS

Conformal volumetric image-guided radiotherapy of the prostate bed leads to low toxicity rates.

Survey of image-guided radiotherapy use in Australia

INTRODUCTION

This study aimed to evaluate the current use of imaging technologies for planning and delivery of radiotherapy (RT) in Australia.

METHODS

An online survey was emailed to all Australian RT centres in August 2015. The survey inquired about imaging practices during planning and treatment delivery processes. Participants were asked about the types of image-guided RT (IGRT) technologies and the disease sites they were used for, reasons for implementation, frequency of imaging and future plans for IGRT use in their department.

RESULTS

The survey was completed by 71% of Australian RT centres. All respondents had access to computed tomography (CT) simulators and regularly co-registered the following scans to the RT: diagnostic CT (50%), diagnostic magnetic resonance imaging (MRI) (95%), planning MRI (34%), planning positron emission tomography (PET) (26%) and diagnostic PET (97%) to aid in tumour delineation. The main reason for in-room IGRT implementation was the use of highly conformal techniques, while the most common reason for under-utilisation was lack of equipment capability. The most commonly used IGRT modalities were kilovoltage (kV) cone-beam CT (CBCT) (97%), kV electronic portal image (EPI) (89%) and megavoltage (MV) EPI (75%). Overall, participants planned to increase IGRT use in planning (33%) and treatment delivery (36%).

CONCLUSIONS

IGRT is widely used among Australian RT centres. On the basis of future plans of respondents, the installation of new imaging modalities is expected to increase for both planning and treatment.

[Image-guided radiotherapy]

The IGRT is described in its various equipment and implementation. IGRT can be based either on ionizing radiation generating 2D imaging (MV or kV) or 3D imaging (CBCT or MV-CT) or on non-ionizing radiation (ultrasound, optical imaging, MRI or radiofrequency). Adaptive radiation therapy is then presented in its principles of implementation. The function of the technicians for IGRT is then presented and the possible dose delivered by the on-board imaging is discussed. The quality control of IGRT devices is finally described.

Current Trends in Sinonasal Imaging

As endoscopic sinus surgery (ESS) has evolved since its introduction to the United States, so has technology for imaging the sinonasal cavities. Although imaging is most frequently performed for evaluating chronic sinusitis refractory to medical therapy, its uses have expanded beyond inflammatory sinus disease. Multidetector Computed Tomography is the current workhorse for both diagnosis and preoperative planning in prospective ESS patients, while MR imaging remains a complementary tool for evaluating suspected tumors or intracranial and orbital complications of rhinosinusitis. In this article, the authors review current trends and potential future directions in the use of these modalities for sinus imaging.

Measurement of eye lens dose for Varian On-Board Imaging with different cone-beam computed tomography acquisition techniques

The objective of this work was to measure patient eye lens dose for different cone-beam computed tomography (CBCT) acquisition protocols of Varian's On-Board Imaging (OBI) system using optically stimulated luminescence dosimeter (OSLD) and to study the variation in eye lens dose with patient geometry and distance of isocenter to the eye lens. During the experimental measurements, OSLD was placed on the patient between the eyebrows of both eyes in line of nose during CBCT image acquisition to measure eye lens doses. The eye lens dose measurements were carried out for three different cone-beam acquisition protocols (standard dose head, low-dose head [LDH], and high-quality head [HQH]) of Varian OBI. Measured doses were correlated with patient geometry and distance between isocenter and eye lens. Measured eye lens doses for standard head and HQH protocols were in the range of 1.8-3.2 mGy and 4.5-9.9 mGy, respectively. However, the measured eye lens dose for the LDH protocol was in the range of 0.3-0.7 mGy. The measured data indicate that eye lens dose to patient depends on the selected imaging protocol. It was also observed that eye lens dose does not depend on patient geometry but strongly depends on distance between eye lens and treatment field isocenter. However, undoubted advantages of imaging system should not be counterbalanced by inappropriate selection of imaging protocol, especially for very intense imaging protocol.

Accounting for patient size in the optimization of dose and image quality of pelvis cone beam CT protocols on the Varian OBI system

OBJECTIVE

The purpose of this study was to develop size-based radiotherapy kilovoltage cone beam CT (CBCT) protocols for the pelvis.

METHODS

Image noise was measured in an elliptical phantom of varying size for a range of exposure factors. Based on a previously defined "small pelvis" reference patient and CBCT protocol, appropriate exposure factors for small, medium, large and extra-large patients were derived which approximate the image noise behaviour observed on a Philips CT scanner (Philips Medical Systems, Best, Netherlands) with automatic exposure control (AEC). Selection criteria, based on maximum tube current-time product per rotation selected during the radiotherapy treatment planning scan, were derived based on an audit of patient size.

RESULTS

It has been demonstrated that 110 kVp yields acceptable image noise for reduced patient dose in pelvic CBCT scans of small, medium and large patients, when compared with manufacturer's default settings (125 kVp). Conversely, extra-large patients require increased exposure factors to give acceptable images. 57% of patients in the local population now receive much lower radiation doses, whereas 13% require higher doses (but now yield acceptable images).

CONCLUSION

The implementation of size-based exposure protocols has significantly reduced radiation dose to the majority of patients with no negative impact on image quality. Increased doses are required on the largest patients to give adequate image quality.

ADVANCES IN KNOWLEDGE

The development of size-based CBCT protocols that use the planning CT scan (with AEC) to determine which protocol is appropriate ensures adequate image quality whilst minimizing patient radiation dose.

Imaging dose from cone beam computed tomography in radiation therapy

Imaging dose in radiation therapy has traditionally been ignored due to its low magnitude and frequency in comparison to therapeutic dose used to treat patients. The advent of modern, volumetric, imaging modalities, often as an integral part of linear accelerators, has facilitated the implementation of image-guided radiation therapy (IGRT), which is often accomplished by daily imaging of patients. Daily imaging results in additional dose delivered to patient that warrants new attention be given to imaging dose. This review summarizes the imaging dose delivered to patients as the result of cone beam computed tomography (CBCT) imaging performed in radiation therapy using current methods and equipment. This review also summarizes methods to calculate the imaging dose, including the use of Monte Carlo (MC) and treatment planning systems (TPS). Peripheral dose from CBCT imaging, dose reduction methods, the use of effective dose in describing imaging dose, and the measurement of CT dose index (CTDI) in CBCT systems are also reviewed.

Radiological Protection in Cone Beam Computed Tomography (CBCT). ICRP Publication 129

The objective of this publication is to provide guidance on radiological protection in the new technology of cone beam computed tomography (CBCT). Publications 87 and 102 dealt with patient dose management in computed tomography (CT) and multi-detector CT. The new applications of CBCT and the associated radiological protection issues are substantially different from those of conventional CT. The perception that CBCT involves lower doses was only true in initial applications. CBCT is now used widely by specialists who have little or no training in radiological protection. This publication provides recommendations on radiation dose management directed at different stakeholders, and covers principles of radiological protection, training, and quality assurance aspects. Advice on appropriate use of CBCT needs to be made widely available. Advice on optimisation of protection when using CBCT equipment needs to be strengthened, particularly with respect to the use of newer features of the equipment. Manufacturers should standardise radiation dose displays on CBCT equipment to assist users in optimisation of protection and comparisons of performance. Additional challenges to radiological protection are introduced when CBCT-capable equipment is used for both fluoroscopy and tomography during the same procedure. Standardised methods need to be established for tracking and reporting of patient radiation doses from these procedures. The recommendations provided in this publication may evolve in the future as CBCT equipment and applications evolve. As with previous ICRP publications, the Commission hopes that imaging professionals, medical physicists, and manufacturers will use the guidelines and recommendations provided in this publication for implementation of the Commission's principle of optimisation of protection of patients and medical workers, with the objective of keeping exposures as low as reasonably achievable, taking into account economic and societal factors, and consistent with achieving the necessary medical outcomes.

Concomitant Imaging Dose and Cancer Risk in Image Guided Thoracic Radiation Therapy

PURPOSE

Kilovoltage cone beam computed tomography (CT) (kVCBCT) imaging guidance improves the accuracy of radiation therapy but imposes an extra radiation dose to cancer patients. This study aimed to investigate concomitant imaging dose and associated cancer risk in image guided thoracic radiation therapy.

METHODS AND MATERIALS

The planning CT images and structure sets of 72 patients were converted to CT phantoms whose chest circumferences (Cchest) were calculated retrospectively. A low-dose thorax protocol on a Varian kVCBCT scanner was simulated by a validated Monte Carlo code. Computed doses to organs and cardiac substructures (for 5 selected patients of various dimensions) were regressed as empirical functions of Cchest, and associated cancer risk was calculated using the published models. The exposures to nonthoracic organs in children were also investigated.

RESULTS

The structural mean doses decreased monotonically with increasing Cchest. For all 72 patients, the median doses to the heart, spinal cord, breasts, lungs, and involved chest were 1.68, 1.33, 1.64, 1.62, and 1.58 cGy/scan, respectively. Nonthoracic organs in children received 0.6 to 2.8 cGy/scan if they were directly irradiated. The mean doses to the descending aorta (1.43 ± 0.68 cGy), left atrium (1.55 ± 0.75 cGy), left ventricle (1.68 ± 0.81 cGy), and right ventricle (1.85 ± 0.84 cGy) were significantly different (P<.05) from the heart mean dose (1.73 ± 0.82 cGy). The blade shielding alleviated the exposure to nonthoracic organs in children by an order of magnitude.

CONCLUSIONS

As functions of patient size, a series of models for personalized estimation of kVCBCT doses to thoracic organs and cardiac substructures have been proposed. Pediatric patients received much higher doses than did the adults, and some nonthoracic organs could be irradiated unexpectedly by the default scanning protocol. Increased cancer risks and disease adverse events in the thorax were strongly related to higher imaging doses and smaller chest dimensions.

Validation of a technique for estimating organ doses for kilovoltage cone-beam CT of the prostate using the PCXMC 2.0 patient dose calculator

The use of cone beam CT in common radiotherapy treatments is increasing with the growth of image guided radiotherapy. Whilst the benefits that this technology offers are clear, such as improved patient positioning prior to treatment, it is always important to consider the implications of such intensive imaging regimes on the patient, especially when considering the fundamental radiation protection requirements for justification and optimisation.The purpose of this study was to develop a technique that uses readily available dose calculation software (PCXMC 2.0) to estimate the organ and effective doses that result from these types of examination in prostate treatments on the Varian OBI system. It has been shown that by separating these types of examinations into 28 different projections, with a range of x-ray beam qualities, it is possible to reproduce the complex geometry that is used on these imaging systems in PCXMC i.e. asymmetric radiation field with a half bowtie filter rotating 360° around the patient.This new technique has been validated with thermo-luminescent dosimeter measurements in the Rando anthropomorphic phantom, and has been shown to give excellent agreement with this established method (R(2) = 0.995). This technique will prove to be valuable to radiotherapy departments that are looking to optimise their CBCT imaging protocols as it allows a rapid evaluation of the impact of any changes on patient dose. It also serves to further highlight the levels of dose that these types of patient are subject to when having daily CBCT scans as part of the treatment, which further reinforces the need for optimisation of both patient dose and image quality on these systems.

Image quality and dose distributions of three linac-based imaging modalities

BACKGROUND AND PURPOSE

Linac-based patient imaging is possible with a variety of techniques using different photon energies. The purpose of this work is to compare three imaging systems operating at 6 MV, flattening free filter (FFF) 1 MV, and 121 kV.

PATIENTS AND METHODS

The dose distributions of all pretreatment set-up images (over 1,000) were retrospectively calculated on the planning computed tomography (CT) images for all patients with prostate and head-and-neck cancer treated at our institution in 2013. We analyzed the dose distribution and the dose to organs at risk.

RESULTS

For head-and-neck cancer patients, the imaging dose from 6-MV cone beam CT (CBCT) reached maximum values at around 8 cGy. The 1-MV CBCT dose was about 63-79 % of the 6-MV CBCT dose for all organs at risk. Planar imaging reduced the imaging dose from CBCT to 30-40 % for both megavoltage modalities. The dose from the kilovoltage CBCT was 4-10 % of the 6-MV CBCT dose. For prostate cancer patients, the maximum dose from 6-MV CBCT reached 13-15 cGy, and was reduced to 66-73 % for 1 MV. Planar imaging reduces the MV CBCT dose to 10-20 %. The kV CBCT dose is 15-20 % of the 6-MV CBCT dose, slightly higher than the dose from MV axes. The dose distributions differ markedly in response to the different beam profiles and dose-depth characteristics.

Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction

OBJECTIVE

To investigate whether planning target volume (PTV) margins may be safely reduced in radiotherapy of localized prostate cancer incorporating daily online tube potential-cone beam CT (CBCT) image guidance and the anticipated benefit in predicted rectal toxicity.

METHODS

The prostate-only clinical target volume (CTV2) and rectum were delineated on 1 pre-treatment CBCT each week in 18 randomly selected patients. By transposing these contours onto the original plan, dose-volume histograms (DVHs) for CTV2 and the rectum were each calculated and combined, for each patient, to produce a single mean DVH representative of the dose delivered over the treatment course. Plans were reoptimized using reduced CTV2 to PTV2 margins and the consequent radiobiological impact modelled by the tumour control probability (TCP) and normal tissue complication probability (NTCP) of the rectum.

RESULTS

All CBCT images were deemed of sufficient quality to identify the CTV and rectum. No loss of TCP was observed when plans using the standard 5-mm CTV2 to PTV2 margin of the centre were reoptimized with a 4- or 3-mm margin. Margin reduction was associated with a significant decrease in rectal NTCP (5-4 mm; p < 0.05 and 5-3 mm; p < 0.01).

CONCLUSION

Using daily online image guidance with CBCT, a reduction in CTV2 to PTV2 margins to 3 mm is achievable without compromising tumour control. The consequent sparing of surrounding normal tissues is associated with reduced anticipated rectal toxicity.

ADVANCES IN KNOWLEDGE

Margin reduction is feasible and potentially beneficial. Centres with image-guided radiotherapy capability should consider assessing whether margin reduction is possible within their institutes.

Measurement of radiotherapy CBCT dose in a phantom using different methods

Cone beam computed tomography (CBCT) is used widely for the precise and accurate patient set up needed during radiation therapy, notably for hypo fractionated treatments, such as intensity modulated radiation therapy and stereotactic radiation therapy. Reported doses associated with CBCT indicate the potential to approach radiation tolerance levels for some critical organs. However while some manufacturers state the CBCT dose for each standard protocol, currently there are no standard or recognised protocols for CBCT dosimetry. This study has applied wide beam computed tomography dosimetry approaches as reported by the International Atomic Energy Agency and the American Association of Physicists in Medicine to investigate dosimetry for the Varian Trilogy linear accelerator with on-board imager v1.5. Three detection methods were used including (i) the use of both 100 mm and 300 mm pencil ionisation chambers, (ii) a 0.6 cm(3) ionisation chamber and (iii) gafchromic film. Measurements were performed using custom built 45 cm long PMMA phantoms as well as standard 15 cm long phantoms for both head and body simulation. The results showed good agreement between each other detector system (within 3 %). The measured CBCT dose for the above methods showed a large difference to the dose stated by Varian, with the measured dose being 40 % over the stated dose for the standard head protocol. This shows the importance of independently verifying the stated dose given by the vendor for standard procedures.

Dose calculation and treatment plan optimization including imaging dose from kilovoltage cone beam computed tomography

BACKGROUND

With the increasing use of cone beam computed tomography (CBCT) for patient position verification and radiotherapy treatment adaptation, there is an increasing need to develop techniques that can take into account concomitant dose using a personalized approach.

MATERIAL AND METHODS

A total of 20 patients (10 pelvis and 10 head and neck) who had undergone radiation therapy using intensity modulated radiation therapy (IMRT) were selected and the dose from kV CBCT was retrospectively calculated using a treatment planning system previously commissioned for this purpose. The imaging dose was added to the CT images used for treatment planning and the difference in its addition prior to and after the planning was assessed.

RESULTS

The additional isocenter dose as a result of daily CBCT is in the order of 3-4 cGy for 35-fraction head and neck and 23-47 cGy for 25-fraction pelvis cases using the standard head and neck and pelvis image acquisition protocols. The pelvic dose is especially dependent on patient size and body mass index (BMI), being higher for patients with lower BMI. Due to the low energy of the kV CBCT beam, the maximum energy deposition is at or near the surface with the highest dose being on the patient's left side for the head and neck (∼7 cGy) and on the posterior for the pelvic cases (∼80 cGy). Addition of imaging dose prior to plan optimization resulted in an average reduction of 4% in the plan monitor units and 5% in the number of control points.

CONCLUSION

Dose from daily kV CBCT has been added to patient treatment plans using previously commissioned kV CBCT beams in a treatment planning system. Addition of imaging dose can be included in IMRT treatment plan optimization and would facilitate customization of imaging protocol based on patient anatomy and location of isocenter.

Investigation into the radiobiological consequences of pre-treatment verification imaging with megavoltage X-rays in radiotherapy

OBJECTIVE

The aim of this study was to investigate the effect of pre-treatment verification imaging with megavoltage X-rays on cancer and normal cell survival in vitro and to compare the findings with theoretically modelled data. Since the dose received from pre-treatment imaging can be significant, the incorporation of this dose at the planning stage of treatment has been suggested.

METHODS

The impact of imaging dose incorporation on cell survival was investigated by clonogenic assay of irradiated DU-145 prostate cancer, H460 non-small-cell lung cancer and AGO-1522b normal tissue fibroblast cells. Clinically relevant imaging-to-treatment times of 7.5 and 15 min were chosen for this study. The theoretical magnitude of the loss of radiobiological efficacy due to sublethal damage repair was investigated using the Lea-Catcheside dose protraction factor model.

RESULTS

For the cell lines investigated, the experimental data showed that imaging dose incorporation had no significant impact on cell survival. These findings were in close agreement with theoretical results.

CONCLUSION

For the conditions investigated, the results suggest that allowance for the imaging dose at the planning stage of treatment should not adversely affect treatment efficacy.

ADVANCES IN KNOWLEDGE

There is a paucity of data in the literature on imaging effects in radiotherapy. This article presents a systematic study of imaging dose effects on cancer and normal cell survival, providing both theoretical and experimental evidence for clinically relevant imaging doses and imaging-to-treatment times. The data provide a firm foundation for further study into this highly relevant area of research.

Comparative dose evaluations between XVI and OBI cone beam CT systems using Gafchromic XRQA2 film and nanoDot optical stimulated luminescence dosimeters

PURPOSE

To investigate the effect of energy (kVp) and filters (no filter, half Bowtie, and full Bowtie) on the dose response curves of the Gafchromic XRQA2 film and nanoDot optical stimulated luminescence dosimeters (OSLDs) in CBCT dose fields. To measure surface and internal doses received during x-ray volume imager (XVI) (Version R4.5) and on board imager (OBI) (Version 1.5) CBCT imaging protocols using these two types of dosimeters.

METHODS

Gafchromic XRQA2 film and nanoDot OSLD dose response curves were generated at different kV imaging settings used by XVI (software version R4.5) and OBI (software version 1.5) CBCT systems. The settings for the XVI system were: 100 kVp∕F0 (no filter), 120 kVp∕F0, and 120 kVp∕F1 (Bowtie filter), and for the OBI system were: 100 kVp∕full fan, 125 kVp∕full fan, and 125 kVp∕half fan. XRQA2 film was calibrated in air to air kerma levels between 0 and 11 cGy and scanned using reflection scanning mode with the Epson Expression 10000 XL flat-bed document scanner. NanoDot OSLDs were calibrated on phantom to surface dose levels between 0 and 14 cGy and read using the inLight(TM) MicroStar reader. Both dosimeters were used to measure in field surface and internal doses in a male Alderson Rando Phantom.

RESULTS

Dose response curves of XRQA2 film and nanoDot OSLDs at different XVI and OBI CBCT settings were reported. For XVI system, the surface dose ranged between 0.02 cGy in head region during fast head and neck scan and 4.99 cGy in the chest region during symmetry scan. On the other hand, the internal dose ranged between 0.02 cGy in the head region during fast head and neck scan and 3.17 cGy in the chest region during chest M20 scan. The average (internal and external) dose ranged between 0.05 cGy in the head region during fast head and neck scan and 2.41 cGy in the chest region during chest M20 scan. For OBI system, the surface dose ranged between 0.19 cGy in head region during head scan and 4.55 cGy in the pelvis region during spot light scan. However, the internal dose ranged between 0.47 cGy in the head region during head scan and 5.55 cGy in the pelvis region during spot light scan. The average (internal and external) dose ranged between 0.45 cGy in the head region during head scan and 3.59 cGy in the pelvis region during spot light scan. Both Gafchromic XRQA2 film and nanoDot OSLDs gave close estimation of dose (within uncertainties) in many cases. Though, discrepancies of up to 20%-30% were observed in some cases.

CONCLUSIONS

Dose response curves of Gafchromic XRQA2 film and nanoDot OSLDs indicated that the dose responses of these two dosimeters were different even at the same photon energy when different filters were used. Uncertainty levels of both dosimetry systems were below 6% at doses above 1 cGy. Both dosimetry systems gave almost similar estimation of doses (within uncertainties) in many cases, with exceptions of some cases when the discrepancy was around 20%-30%. New versions of the CBCT systems (investigated in this study) resulted in lower imaging doses compared with doses reported on earlier versions in previous studies.